Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Price Performance

Shares of PVLA stock opened at $118.84 on Tuesday. The stock has a market cap of $1.70 billion, a P/E ratio of -28.50 and a beta of -0.14. The company has a fifty day moving average price of $118.40 and a two-hundred day moving average price of $109.24. Palvella Therapeutics, Inc. has a one year low of $20.35 and a one year high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities research analysts anticipate that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PVLA. Group One Trading LLC lifted its holdings in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. KBC Group NV acquired a new position in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Price T Rowe Associates Inc. MD increased its position in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after acquiring an additional 433 shares during the period. Bank of America Corp DE grew its position in shares of Palvella Therapeutics by 12.3% during the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after purchasing an additional 515 shares in the last quarter. Finally, Deutsche Bank AG grew its position in shares of Palvella Therapeutics by 8.7% during the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright boosted their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. Truist Financial set a $210.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. Mizuho increased their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.